• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Better Therapeutics Appoints Dr. Risa Lavizzo-Mourey to its Board of Directors

    4/20/21 8:00:00 AM ET
    $MRK
    $GE
    $INTC
    $MCAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Consumer Electronics/Appliances
    Technology
    Get the next $MRK alert in real time by email

    Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also serve as Compensation Committee chair.

    "Dr. Lavizzo-Mourey brings critical insights into health policy, as well as her background as a primary care physician at a critical juncture for Better Therapeutics," said David Perry, co-founder and chairman of Better Therapeutics. "Her experience and counsel will help us establish our prescription digital therapeutics as the new standard of care for people with cardiometabolic diseases."

    Dr. Lavizzo-Mourey joins the board after previously serving in various high-level roles under three presidential administrations, including as Deputy Administrator for the Agency for Health Care Policy and Research under President George H.W. Bush's administration, as quality of care chair for President Bill Clinton's panels on health care, and on President Obama's Council on Fitness, Sports and Nutrition. Her career combines geriatric medicine and health policy, focusing on disease, disability, prevention, and healthcare issues among minorities. She brings hands-on experience in the fields of research and academia, as a primary care provider, and health policy on a national level with an acute understanding of minority suffering and disenfranchisement.

    "I welcome this opportunity to extend my expertise and contribute to the success of Better Therapeutics, which I believe has the potential to truly be transformative in treating cardiometabolic diseases," said Dr. Lavizzo-Mourey.

    Dr. Lavizzo-Mourey currently serves as an independent director and Nominating & Governance Committee member for Intel (NYSE:INTC), an independent director and Compensation & Benefits Committee member for Merck (NYSE:MRK), and as an independent director and Governance & Public Affairs committee member for General Electric (NYSE:GE).

    Risa is the recipient of numerous awards, including twenty honorary doctorates. She has appeared on Forbes' list of the most important women in the world eight times, and as one of Modern Healthcare's one hundred most influential people in health care eleven times.

    "Prescription digital therapeutics is a rapid evolving sector of the life science industry, and Better Therapeutics' digitally-delivered cognitive behavioral therapy that addresses the root causes of disease has the potential to become standard practice in cardiometabolic disease treatment," added Dr. Lavizzo-Mourey.

    Boardspan Inc. served as an advisor to Better Therapeutics in this appointment.

    About Better Therapeutics

    Better Therapeutics has created a platform for the development of prescription digital therapeutics (PDT) for the treatment of diabetes, heart disease and other cardiometabolic conditions. The Better Therapeutics platform blends clinical, behavioral and psychological inputs into a series of therapy lessons and skill-building modules designed to isolate and shift the underlying thoughts and beliefs which guide diet and lifestyle behaviors that are the root causes of a wide range of cardiometabolic diseases. The delivery of behavioral therapy enables changes in neural pathways of the brain and leads to behavioral change. These therapies and the resulting changes hold the potential to lower healthcare costs to treat these conditions and improve patient health.

    Better Therapeutics' first PDT (BT-001) is being evaluated in a pivotal trial as a treatment for type 2 diabetes used under physician supervision. It is anticipated that following marketing authorization, primary care providers will prescribe, and insurers will reimburse Better Therapeutics' PDTs much like they would a traditional medication.

    About Mountain Crest Acquisition Corp. II

    Mountain Crest Acquisition Corp. II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Mountain Crest II's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the company intends to focus on operating businesses in North America.

    Additional Information

    On April 6, 2021, Better Therapeutics entered into a definitive merger agreement with Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) ("Mountain Crest II"), a special purpose acquisition company for a proposed business combination.

    In connection with the proposed business combination between Mountain Crest II and Better Therapeutics, Mountain Crest II will file a registration statement on Form S-4 containing a proxy statement/prospectus (the "Form S-4") with the Securities and Exchange Commission (the "SEC"). The Form S-4 will include a proxy statement to be distributed to holders of Mountain Crest II's common stock in connection with Mountain Crest II's solicitation of proxies for the vote by Mountain Crest II's shareholders with respect to the proposed transaction and other matters as described in the Form S-4, as well as the prospectus relating to the offer of securities to be issued to Better Therapeutics' stockholders in connection with the proposed business combination. After the Form S-4 has been filed and declared effective, Mountain Crest II will mail a definitive proxy statement, when available, to its stockholders. Investors and security holders and other interested parties are urged to read the Form S-4, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Mountain Crest II, Better Therapeutics and the proposed business combination. Additionally, Mountain Crest II will file other relevant materials with the SEC in connection with the business combination. Copies of these documents may be obtained free of charge at the SEC's web site at www.sec.gov. Securityholders of Mountain Crest II are urged to read the Form S-4 and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information. The information contained on, or that may be accessed through, the website referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

    Participants in the Solicitation

    Mountain Crest and Better Therapeutics and their respective directors and executive officers may be deemed participants in the solicitation of proxies with respect to the proposed business combination under the rules of the SEC. Securityholders may obtain more detailed information regarding the names, affiliations, and interests of certain of Mountain Crest's executive officers and directors in the solicitation by reading Mountain Crest's Form S-4 and other relevant materials filed with the SEC in connection with the proposed business combination when they become available. Information about Mountain Crest II's directors and executive officers and their ownership of Mountain Crest II common stock is set forth in Mountain Crest II's annual report on Form 10-K for the year ended December 31, 2020, dated March 30, 2021 , as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of that filing. Other information regarding the interests of Mountain Crest II's participants in the proxy solicitation, which in some cases, may be different than those of their stockholders generally, will be set forth in the Form S-4 relating to the proposed business combination when it becomes available. These documents can be obtained free of charge at the SEC's web site at www.sec.gov.

    Better Therapeutics and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Mountain Crest II in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Form S-4 for the proposed business combination.

    Non-Solicitation

    This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

    Forward-Looking Statements

    Certain statements made in this press release are "forward-looking statements" within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about patient enrollment and potential clinical outcomes. In addition, any statements that refer to projections (including EBITDA, adjusted EBITDA, EBITDA margin and revenue projections), forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005351/en/

    Get the next $MRK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRK
    $GE
    $INTC
    $MCAD

    CompanyDatePrice TargetRatingAnalyst
    Intel Corporation
    $INTC
    7/22/2025$25.00Hold
    Loop Capital
    Intel Corporation
    $INTC
    5/21/2025$23.00Hold
    Deutsche Bank
    GE Aerospace
    $GE
    5/19/2025Buy → Neutral
    Northcoast
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Intel Corporation
    $INTC
    4/30/2025$18.00Sell
    Seaport Research Partners
    Intel Corporation
    $INTC
    4/25/2025$23.00 → $22.00Neutral
    Mizuho
    Intel Corporation
    $INTC
    4/25/2025$22.00 → $21.00Neutral
    UBS
    Intel Corporation
    $INTC
    4/25/2025$25.00 → $22.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MRK
    $GE
    $INTC
    $MCAD
    SEC Filings

    See more
    • SEC Form IRANNOTICE filed by Intel Corporation

      IRANNOTICE - INTEL CORP (0000050863) (Filer)

      7/24/25 4:21:52 PM ET
      $INTC
      Semiconductors
      Technology
    • GE Aerospace filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GENERAL ELECTRIC CO (0000040545) (Filer)

      7/24/25 4:11:07 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • SEC Form 10-Q filed by Intel Corporation

      10-Q - INTEL CORP (0000050863) (Filer)

      7/24/25 4:08:10 PM ET
      $INTC
      Semiconductors
      Technology

    $MRK
    $GE
    $INTC
    $MCAD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Gelsinger Patrick P bought $251,198 worth of shares (11,150 units at $22.53), increasing direct ownership by 12% to 105,033 units (SEC Form 4)

      4 - INTEL CORP (0000050863) (Issuer)

      11/6/24 4:06:28 PM ET
      $INTC
      Semiconductors
      Technology

    $MRK
    $GE
    $INTC
    $MCAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intel Reports Second-Quarter 2025 Financial Results

      News Summary Second-quarter revenue was $12.9 billion, flat year-over-year (YoY). Second-quarter earnings (loss) per share (EPS) attributable to Intel was $(0.67); non-GAAP EPS attributable to Intel was $(0.10). $(0.45) impact to GAAP EPS attributable to Intel from $1.9 billion of restructuring charges; $(0.23) and $(0.20) impact to GAAP and non-GAAP EPS attributable to Intel, respectively, from $800 million of impairment charges and $200 million in one-time period costs. Forecasting third-quarter 2025 revenue of $12.6 billion to $13.6 billion; expecting third-quarter EPS attributable to Intel of $(0.24) and non-GAAP EPS attributable to Intel of $0.00. Taking actions to drive

      7/24/25 4:01:00 PM ET
      $INTC
      Semiconductors
      Technology
    • Mobileye Releases Second Quarter 2025 Results, Updates Full-year 2025 Outlook, and Provides Business Overview

      Revenue of $506 million in the second quarter increased 15% year over year compared to Q2 2024 on strong demand across the business. Operating Income (Loss) and Adjusted Operating Income improved 21% and 34%, respectively. Diluted EPS (GAAP) was $(0.08) and Adjusted Diluted EPS (Non-GAAP) was $0.13 in the second quarter of 2025. Continued strength in supply-demand dynamics supports an upward revision of our full-year 2025 revenue outlook to $1,765 million - $1,885 million, implying 7% - 14% year-over-year revenue growth. Generated net cash from operating activities of $322 million in the six months ended June 28, 2025. Our balance sheet is strong with $1.7 billion of cash and cash

      7/24/25 7:00:00 AM ET
      $INTC
      $MBLY
      Semiconductors
      Technology
      Computer Software: Prepackaged Software
    • Merck Announces Fourth-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

      7/22/25 11:53:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $GE
    $INTC
    $MCAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Loop Capital initiated coverage on Intel with a new price target

      Loop Capital initiated coverage of Intel with a rating of Hold and set a new price target of $25.00

      7/22/25 7:53:10 AM ET
      $INTC
      Semiconductors
      Technology
    • Deutsche Bank resumed coverage on Intel with a new price target

      Deutsche Bank resumed coverage of Intel with a rating of Hold and set a new price target of $23.00

      5/21/25 8:58:20 AM ET
      $INTC
      Semiconductors
      Technology
    • GE Aerospace downgraded by Northcoast

      Northcoast downgraded GE Aerospace from Buy to Neutral

      5/19/25 8:49:04 AM ET
      $GE
      Consumer Electronics/Appliances
      Technology

    $MRK
    $GE
    $INTC
    $MCAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Seidman Christine E

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:08:35 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Glocer Thomas H

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:06:38 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Coe Mary Ellen

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      7/2/25 12:04:07 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $GE
    $INTC
    $MCAD
    Leadership Updates

    Live Leadership Updates

    See more
    • Intel Appoints Sales and Engineering Leaders

      Intel today announced a series of leadership appointments aligned with its focus on strengthening customer relationships and becoming a more engineering-focused company. Greg Ernst, a respected sales leader with more than 20 years of Intel experience, has been named chief revenue officer. In addition, Srinivasan Iyengar, Jean-Didier Allegrucci and Shailendra Desai are joining Intel in key engineering leadership roles. "We see significant opportunities ahead to strengthen our product offerings and meet the changing needs of our customers," said Lip-Bu Tan, CEO of Intel. "Greg, Srini, J-D and Shailendra are highly accomplished leaders with strong reputations across our ecosystem, and they

      6/18/25 9:30:00 AM ET
      $INTC
      Semiconductors
      Technology
    • ISS and Glass Lewis Join ADL and JLens in Recommending AGAINST Anti-Israel Shareholder Proposals at Intel, General Dynamics and Lockheed Martin

      Reiterates Call for Shareholders to Reject Proposals Motivated by Antisemitic Boycott, Divestment and Sanctions (BDS) Movement ADL (Anti-Defamation League) and its affiliate, Jlens, welcome the decisions of the two leading independent proxy advisory firms, Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Glass Lewis"), to recommend that investors vote AGAINST anti-Israel shareholder proposals at the upcoming annual meetings of Intel Corporation (NASDAQ:INTC), General Dynamics (NYSE:GD) and Lockheed Martin Corporation (NYSE:LMT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505942003/en/ ADL and its Regist

      5/5/25 8:00:00 AM ET
      $GD
      $INTC
      $LMT
      Marine Transportation
      Industrials
      Semiconductors
      Technology
    • Intel Appoints Lip-Bu Tan as Chief Executive Officer

      Tan to join Intel board of directors Intel Corporation (NASDAQ:INTC) today announced that its board of directors has appointed Lip-Bu Tan, an accomplished technology leader with deep semiconductor industry experience, as chief executive officer, effective March 18. He succeeds Interim Co-CEOs David Zinsner and Michelle (MJ) Johnston Holthaus. Tan will also rejoin the Intel board of directors after stepping down from the board in August 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312399008/en/Lip-Bu Tan was appointed chief executive officer of Intel Corporation in March 2025. He also serves on the company's board of d

      3/12/25 4:15:00 PM ET
      $INTC
      Semiconductors
      Technology

    $MRK
    $GE
    $INTC
    $MCAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GE Aerospace

      SC 13G/A - GENERAL ELECTRIC CO (0000040545) (Subject)

      11/12/24 12:54:20 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology
    • SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

      SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

      2/13/24 4:55:49 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by General Electric Company (Amendment)

      SC 13G/A - GENERAL ELECTRIC CO (0000040545) (Subject)

      2/13/24 4:55:49 PM ET
      $GE
      Consumer Electronics/Appliances
      Technology

    $MRK
    $GE
    $INTC
    $MCAD
    Financials

    Live finance-specific insights

    See more
    • Intel Reports Second-Quarter 2025 Financial Results

      News Summary Second-quarter revenue was $12.9 billion, flat year-over-year (YoY). Second-quarter earnings (loss) per share (EPS) attributable to Intel was $(0.67); non-GAAP EPS attributable to Intel was $(0.10). $(0.45) impact to GAAP EPS attributable to Intel from $1.9 billion of restructuring charges; $(0.23) and $(0.20) impact to GAAP and non-GAAP EPS attributable to Intel, respectively, from $800 million of impairment charges and $200 million in one-time period costs. Forecasting third-quarter 2025 revenue of $12.6 billion to $13.6 billion; expecting third-quarter EPS attributable to Intel of $(0.24) and non-GAAP EPS attributable to Intel of $0.00. Taking actions to drive

      7/24/25 4:01:00 PM ET
      $INTC
      Semiconductors
      Technology
    • Mobileye Releases Second Quarter 2025 Results, Updates Full-year 2025 Outlook, and Provides Business Overview

      Revenue of $506 million in the second quarter increased 15% year over year compared to Q2 2024 on strong demand across the business. Operating Income (Loss) and Adjusted Operating Income improved 21% and 34%, respectively. Diluted EPS (GAAP) was $(0.08) and Adjusted Diluted EPS (Non-GAAP) was $0.13 in the second quarter of 2025. Continued strength in supply-demand dynamics supports an upward revision of our full-year 2025 revenue outlook to $1,765 million - $1,885 million, implying 7% - 14% year-over-year revenue growth. Generated net cash from operating activities of $322 million in the six months ended June 28, 2025. Our balance sheet is strong with $1.7 billion of cash and cash

      7/24/25 7:00:00 AM ET
      $INTC
      $MBLY
      Semiconductors
      Technology
      Computer Software: Prepackaged Software
    • Merck Announces Fourth-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

      7/22/25 11:53:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care